Cholecystokinin Antagonist Reduces Pancreatic Cancer Risk in Rats
Author Information
Author(s): P. Watanapal, B. Flaks, H. Oztas, P.H. Deprez, J. Calam, R.C.N. Williamson
Primary Institution: Royal Postgraduate Medical School, Hammersmith Hospital
Hypothesis
Hypercholecystokininaemia explains the enhancing effect of pancreatobiliary diversion on pancreatic carcinogenesis induced by azaserine in rats.
Conclusion
The cholecystokinin antagonist CR-1409 significantly inhibited the development of precancerous lesions in the pancreas of rats subjected to pancreatobiliary diversion.
Supporting Evidence
- CR-1409 reduced the number of observed acidophilic atypical acinar cell foci by 90%.
- CR-1409 reduced the mean focal diameter of each lesion by 18%.
- CR-1409 reduced the mean focal volume by 58%.
- PBD quadrupled circulating CCK concentrations.
Takeaway
This study found that a drug can help stop the growth of early signs of pancreatic cancer in rats that had surgery to change how their bile flows.
Methodology
Male Wistar rats were treated with azaserine and subjected to either pancreatobiliary diversion or sham surgery, followed by administration of a cholecystokinin antagonist or saline.
Limitations
The study was conducted on a specific strain of rats, which may limit the generalizability of the findings.
Participant Demographics
Male Wistar rats aged 4 weeks, weighing 70-100 g.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website